Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Single-center, Phase Ib/II Clinical Trial of PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Next Previous
X
Search
Trial Profile

A Single Arm, Single-center, Phase Ib/II Clinical Trial of PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Parsaclisib (Primary) ; Tucidinostat (Primary)
  • Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 06 May 2024 Planned primary completion date changed from 1 Feb 2024 to 30 Jun 2024.
    • 12 Dec 2023 preliminary Results ( From March 2022 to July 27, 2023 (date cut-off), n=11) assessing safety and efficacy of parsaclisib with HDAC inhibitor (HDACi) chidamide in r/r PTCL presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 06 Dec 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top